COMMUNIQUÉS West-GlobeNewswire

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
31/07/2026
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination with [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/07/2026
VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Precipio Announces Q2-2026 Shareholder Update Call
31/07/2026
Conference Call will be held on August 17th, 2026, at 5:00 PM EDT NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 [...]
EUROAPI_Availability of 2026 Half-year results financial report
31/07/2026
Press Release Paris, 31 July 2026 Availability of 2026 Half-Year Financial Report EUROAPI posted today its 2026 condensed Half Year Consolidated Financial Statements for the six months ended June 30, 2026. This document [...]
EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026
31/07/2026
Communiqué de presse Paris, le 31 juillet 2026 Mise à disposition du Rapport financier semestriel 2026 EUROAPI a mis en ligne ce jour ses Etats Financiers semestriels consolidés condensés 2026 pour la période close le [...]
Human Appeal USA Announces "The Biggest Comedy Show" 2026 Tour: A 25-City Nationwide Event Where Every Laugh Gives Back to Global Humanitarian Relief
31/07/2026
MISSION VIEJO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Human Appeal USA, a humanitarian nonprofit, announced the Biggest Comedy Show 2026 tour, which will launch this fall across 25 U.S. cities. The tour unites [...]
Moleculin Announces Pricing of $9.3 Million Public Offering
31/07/2026
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of [...]
Turkish Airlines Sports Club Women’s Volleyball Team Completes Pre-Season Health Checks at Medicana
31/07/2026
The renewed healthcare sponsorship brings together one of Turkiye’s leading volleyball teams and Medicana Health Group’s multidisciplinary expertise in athlete health and preventive care ISTANBUL, July 31, 2026 (GLOBE [...]
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
31/07/2026
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– TUCSON, Ariz., July 31, 2026 (GLOBE NEWSWIRE) -- [...]
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
31/07/2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 [...]
J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
31/07/2026
TAICHUNG CITY, Taiwan, July 31, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today announced that it has received a written decision from the Nasdaq Hearings Panel [...]
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
31/07/2026
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
31/07/2026
Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, [...]
Ocugen to Participate in Upcoming August Investor Conferences
31/07/2026
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Radiopharm Theranostics Reports Business Update
31/07/2026
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of [...]
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
31/07/2026
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
31/07/2026
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or [...]
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
31/07/2026
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it [...]
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
31/07/2026
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]

Pages